Drug Eruption and Interactions - PHARMACEUTICAL REVIEW

SOLIFENACIN
Trade name: Vesicare (GSK)
Indications: Overactive bladder
Category: Muscarinic antagonist
Half-life: 45–68 hours
Clinically important, potentially hazardous interactions
with: atazanavir, carbamazepine, clarithromycin, indinavir,
itraconazole, ketoconazole, nefazodone, nelfinavir, phenobarbital,
phenytoin, rifabutin, rifampin, rifapentine, ritonavir, saquinavir, St
John’s wort, troleandomycin, voriconazole
Reactions
Mucosal
Xerostomia (11–27%)
(2005): Med Lett Drugs Ther 47(1204), 23
(2005): Simpson D+, Drugs Aging 22(12), 1061
(2004): Chapple CR+, BJU Int 93(3), 303
(2004): Sand PK, JAmAcadNursePract16(10), 8
(2004): Smulders RA+, J Clin Pharmacol 44(9), 1023
Eyes
Vision blurred (4–5%)
(2005): Simpson D+, Drugs Aging 22(12), 1061
Xerophthalmia (0.3–1.6%)
Other
Abdominal pain (1.2–1.9%)
Cough (0.2–1.1%)
SOMATROPIN
Trade names: Genotropin (Pfizer); Growject BC; Humatrope
(Lilly); Norditropin (Novo Nordisk); Norditropin Simplexx;
Nutropin (Genentech); Nutropin AQ; Saizen (Merck); Scitropin;
Serostim (Merck); Tev-Tropin (Teva)
Indications: Growth failure, growth hormone deficiency, short
stature (in Turner’s syndrome), muscle wasting (in HIV positive
patients)
Category: Growth hormone analog
Half-life: 0.4 hours (IV); 3 hours (subcutaneous)
Clinically important, potentially hazardous interactions
with: glucocorticoids, insulin detemir, insulin glulisine
Reactions
Skin
Acanthosis nigricans
(1999): Downs AM+, Br J Dermatol 141(2), 390
Edema (11.4%)
(2002): Bryant J+, J Endocrinol 175(2), 545
Lupus erythematosus
(2001): Bae YS+, Lupus 10(6), 448 (flare)
Peripheral edema (18.2%)
Pruritus
Rash (sic)
Urticaria
Other
Cough
Death (in critically ill patients)
(2004): Mills JL+, JPediatr144(4), 430
(2004): Vliet GV+, JPediatr144(1), 129
(2000): Osterziel KJ+, NEnglJMed342(2), 134
(2000): Van den Berge G, NEnglJMed342(2), 135
(1999): Takala J+, NEnglJMed341(11), 785
Gynecomastia
(1998): Sullivan DH+, J Gerontol A Biol Sci Med Sci 53(3), M183
Injection-site inflammation
Injection-site pain
Myalgia/Myositis/Myopathy/Myotoxicity (9.1%)
Pain (13.6%)
SORAFENIB
Synonym: BAY 43-9006
Trade name: Nexavar (Bayer)
Indications: Advanced renal cell carcinoma
Category: Tyrosine kinase inhibitor
Half-life: 25–48 hours
Clinically important, potentially hazardous interactions
with: doxorubicin, warfarin
Reactions
SORAFENIB 501
Skin
Acne (1–10%)
Actinic keratoses
(2006): Lacouture ME+, Clin Exp Dermatol 31(6), 783
(inflammation of)
Desquamation (40%)
Eczema (10%)
Erythema multiforme (